Sign inCreate account

Report workspace tools

NCT01790282COMPLETEDanonymous

Is E2 Luteal Support in High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Cycle Outcome ? A Randomized Clinical Trial

Sponsor

Source record

Mansoura Integrated Fertility Center

Phase

Source record

NA

Modality

AI-normalized

small molecule

Target

AI-normalized

Luteal phase support in high responder ICSI cycles

Indication / condition

AI-normalized

IVF

Intervention

Source record

estradiol plus progesterone 100 mg IM injection, Progesterone IM of 100 mg

Source & freshness

Source record

NCT ID

NCT01790282

Original source

ClinicalTrials.gov

Source last updated

Jun 21, 2022

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01790282

Title

Is E2 Luteal Support in High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Cycle Outcome ? A Randomized Clinical Trial

Sponsor

Mansoura Integrated Fertility Center

Status

COMPLETED

Phase

NA

Condition raw

IVF

Condition normalized

IVF

Modality raw

IVF

Modality normalized

small molecule

Target raw

Luteal phase support in high responder ICSI cycles

Target normalized

Luteal phase support in high responder ICSI cycles

Interventions

estradiol plus progesterone 100 mg IM injection, Progesterone IM of 100 mg

Public preview

Source record

This clinical trial investigates the impact of adding estradiol (E2) to progesterone (P4) for luteal phase support in high ovarian responders undergoing ICSI. The study aims to clarify conflicting evidence regarding the efficacy of E2 in improving pregnancy outcomes.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Is E2 Luteal Support in High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Cycle Outcome ? A Randomized Clinical Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01790282

Status

COMPLETED

Phase

NA

Sponsor

Mansoura Integrated Fertility Center

Executive brief

Investment-Ready Snapshot

This clinical trial investigates the impact of adding estradiol (E2) to progesterone (P4) for luteal phase support in high ovarian responders undergoing ICSI. The study aims to clarify conflicting evidence regarding the efficacy of E2 in improving pregnancy outcomes.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 21, 2022
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01790282

Indication

IVF

Modality

small molecule

Target

Luteal phase support in high responder ICSI cycles

Intervention

estradiol plus progesterone 100 mg IM injection, Progesterone IM of 100 mg

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.